NEW
YORK, Dec. 19, 2024 /PRNewswire/ -- The Gross
Law Firm issues the following notice to shareholders of Applied
Therapeutics, Inc. (NASDAQ: APLT).
Shareholders who purchased shares of APLT during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/applied-therapeutics-inc-loss-submission-form/?id=117284&from=4
CLASS PERIOD: January 3,
2024 to December 2, 2024
ALLEGATIONS: According to the complaint, on November 27, 2024, Applied Therapeutics issued a
press release announcing that it had received a Complete Response
Letter (CRL) for the New Drug Application (NDA) for govorestat, the
Company's lead drug candidate. The CRL indicated that the FDA
completed its review of the application and determined that it was
unable to approve the NDA in its current form citing deficiencies
in the clinical application. Following this news, the price of
Applied Therapeutics' common stock declined dramatically. From a
closing market price of $10.21 per
share on November 26, 2024, Applied
Therapeutics' stock price fell to $8.57 per share on November 27, 2024 before falling further to
$2.03 on November 29, 2024 and $1.75 per share on December 2, 2024, a total decline of more than
80%. After market hours on December 2,
2024, Applied Therapeutics disclosed it received a "warning
letter" from the FDA referring to the clinical trial issues
underlying the CRL. Applied Therapeutics' disclosure of the
"warning letter" prompted a further decline in the stock price as
investors discovered the seriousness and severity of the Company's
clinical trial errors. From a closing market price of $1.75 per share on December 2, 2024, Applied Therapeutics' stock
price fell to $1.69 per share on
December 3, 2024 before falling
further to $1.38 per share on
December 4, 2024 and $1.29 per share on December 5, 2024.
DEADLINE: February 18, 2025
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/applied-therapeutics-inc-loss-submission-form/?id=117284&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of APLT during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is February 18, 2025. There is no
cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law
Firm is committed to ensuring that companies adhere to responsible
business practices and engage in good corporate citizenship. The
firm seeks recovery on behalf of investors who incurred losses when
false and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download
multimedia:https://www.prnewswire.com/news-releases/shareholders-that-lost-money-on-applied-therapeutics-incaplt-should-contact-the-gross-law-firm-about-pending-class-action---aplt-302335745.html
SOURCE The Gross Law Firm